Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a Healthcare company (Biotechnology) with a market capitalization of $187M. The Maz Rating grades it against the other companies in its sector.
Cartesian Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.12, Cartesian Therapeutics, Inc. trades at 180.9x sales. Over the last twelve months it generated about $1M of revenue and a net loss of $151M. It runs an operating margin of -10009.2% and a net margin of -12635.1%. It shows return on equity of 97.7%, return on invested capital of -33.8% and a free cash flow yield of -47.9%. On the balance sheet: a debt-to-equity ratio of -0.46 and a current ratio of 8.38. Over the past 52 weeks the share price ranged from $5.60 to $11.00, with a beta of 0.62.
Cartesian Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.